Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition of leukotrienes antagonist oral liquid

A technology of oral liquid and composition, which is applied in the field of anti-allergic oral liquid composition, and can solve problems such as difficulty in swallowing pills

Inactive Publication Date: 2009-06-17
CENT LAB INC
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of lozenges is very inconvenient for asthmatic children, especially children with asthma under 6 years old or elderly asthmatics. Difficulty swallowing, so must be given as a powder

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition of leukotrienes antagonist oral liquid
  • Composition of leukotrienes antagonist oral liquid

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Dissolve Montelukast sodium salt in propylene glycol, dissolve dipotassium hydrogen phosphate, potassium dihydrogen phosphate, sodium saccharin, sodium benzoate, food coloring and spices in water, adjust the concentration of the aqueous solution with 1N sodium hydroxide aqueous solution pH value to pH9~10. After mixing the aqueous phase and the organic phase, the pH value of the solution was adjusted to pH 9-10 with 1N sodium hydroxide aqueous solution, and the concentration of Montelukast sodium salt was 0.2% w / v, which was completely dissolved. Stability tests were performed at 40°C and 60°C, respectively. After storage at 40°C for 150 days, the concentration of Montelukast sodium salt in the solution did not change; after storage at 60°C for 120 days, the concentration of Montelukast sodium salt in the solution did not change either.

[0032] The concentration of the phosphate-containing component in the aqueous solution is about 0.5-7% w / v. The concentration of th...

Embodiment 2

[0034] Dissolve Montelukast sodium salt in propylene glycol, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, sodium saccharin, sodium benzoate, Tween 80, food coloring and spices in water, and add 1N sodium hydroxide Aqueous solution Adjust the pH value of the aqueous solution to pH9-10. After mixing the aqueous phase and the organic phase, the pH value of the solution was adjusted to pH 9-10 with 1N sodium hydroxide aqueous solution, and the concentration of Montelukast sodium salt was 0.2% w / v, which was completely dissolved. Stability tests were performed at 40°C and 60°C, respectively. After storage at 40°C for 150 days, the concentration of Montelukast sodium salt in the solution did not change; after storage at 60°C for 120 days, the concentration of Montelukast sodium salt in the solution did not change either.

[0035] The concentration of the phosphate-containing component in the aqueous solution is about 0.5-7% w / v. In this embodiment, the concentra...

Embodiment 3

[0037] Dissolve Montelukast sodium salt in propylene glycol, dissolve boric acid, potassium chloride, saccharin sodium salt, sodium benzoate, food coloring and spices in water, and adjust the pH value of the aqueous solution to pH9~10. After mixing the aqueous phase and the organic phase, the pH value of the solution was adjusted to pH 9-10 with 1N aqueous sodium hydroxide solution, and the concentration of Montelukast sodium salt was 0.1% w / v, which was completely dissolved. Stability tests were performed at 40°C and 60°C, respectively. After storage at 40°C for 45 days, the concentration of Montelukast sodium salt in the solution did not change; after storage at 60°C for 45 days, the concentration of Montelukast sodium salt in the solution did not change either.

[0038] The concentration of the borate-containing component in the aqueous solution is about 0.1-3% w / v. The concentration of the borate-containing component in this example is about 0.31% w / v. And the consumpti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an oral liquid of leukotriene antagonist against allergy, inflammation, asthma that can be used as cell protecting agent, comprising at least a buffer solution and Montelukast dissolved in the buffer solution and its pharmaceutically acceptable salts. The pH of the buffer solution is between 7-11, and the buffer solution includes at least water, pharmaceutically acceptable alcohols, buffering agents and pharmaceutically acceptable additives.

Description

technical field [0001] The invention relates to a composition of an antiallergic oral liquid, in particular to a composition of an oral liquid of a leukotriene antagonist and inhibitor. Background technique [0002] In recent years, the number of patients with allergic diseases has increased significantly, such as hay fever, allergic rhinitis, urticaria, and asthma. The types, symptoms, and degrees of allergic diseases vary widely. Taking asthma as an example, there are currently about 150,000,000 asthmatics in the world, and the number of deaths due to asthma is about 200,000 each year, and the global asthmatics are growing at a rate of 20-50% per decade. Increase, the medical expenses spent on such chronic diseases are quite huge. Every year, the United States spends about 6 billion U.S. dollars on asthma medical expenses, Germany 3 billion U.S. dollars, the United Kingdom 1.6 billion U.S. dollars, and about 2 billion Taiwan dollars in this country. , of which the annual ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/47A61P37/08
Inventor 张琴音
Owner CENT LAB INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com